A continuing medical education and nursing continuing professional development activity provided by NAMCP and AAMCN.
This activity is an archive from the live session from the 2025 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.
This activity is valid from March 1, 2026 to March 1, 2027
Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the evaluation and post test. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete it. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the "download" button after completing the post test.
Audience: This activity is intended for healthcare professionals practicing in managed care environments.
This activity is supported by an educational grant from
AstraZeneca
Description:
Diffuse Large B-cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma originating from abnormal B lymphocytes. It is an aggressive blood cancer but can be cured with early detection and treatment. Cancerous white blood cells enlarge lymph nodes and can spread to the spleen, liver, bone marrow, or other organs. In the US, about 20,000 people are diagnosed with DLBCL annually. Symptoms vary depending on the disease's location and spread in the body. Significant progress has been made in treating DLBCL, allowing many patients to benefit from current treatment options and achieve remission when diagnosed early. Healthcare professionals are continuously exploring new treatment approaches, such as immunotherapies and molecularly targeted therapies. Recently, several new treatments have been introduced for patients with DLBCL, including BTK inhibitors, used both alone and in combination. These novel treatments provide clinicians with various options to enhance patient outcomes.
Upon completion of this activity, participants will be able to:
Faculty:
John N. Allan, MD
Associate Professor of Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Allan has served as a consultant for AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeOne Medicine, Genentech, Janssen, Lilly, Merck, NeoGenomics, Pfizer, and Pharmacyclics. He has received grant/research support from BeOne Medicine, BMS, and Genentech. All relevant financial relationships have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each physician should claim credit commensurate with the extent of their participation in the activity.
The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.
NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.
This activity is supported by an educational grant from
AstraZeneca
NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.